Kliesch U, Roupova I, Adler I D
Mutat Res. 1982 Oct-Nov;102(3):265-73. doi: 10.1016/0165-1218(82)90136-7.
The cytogenetic effects, in vivo, of the polycyclic hydrocarbon benzo[a]pyrene were studied in adult male mice by chromosome analysis and the micronucleus test. To establish the appropriate time for bone-marrow sampling, the interval between treatment and preparation was varied. The maximal response in the micronucleus test was found 36 h after treatment versus 30 h when chromosomal aberrations were analyzed. In the micronucleus test the lowest effective dose was 25 mg/kg, whereas a significant effect (P less than 0.001) was observed at 6.25 mg/kg when aberrations were used as the mutagenic end-point. The results show that, with single treatments and different sampling intervals applied in both tests, aberration analysis had a higher resolving power than the micronucleus test at the time of maximal response. A suitable protocol for routine application of the 2 bone-marrow tests is discussed in view of the guidelines presently under preparation in the EEC and the OECD. Arguments are presented against a sub-acute treatment regimen and for a single treatment regimen with multiple sampling intervals.
通过染色体分析和微核试验，研究了多环烃苯并[a]芘对成年雄性小鼠的体内细胞遗传学效应。为确定骨髓取样的合适时间，改变了处理与制片之间的间隔时间。微核试验中的最大反应出现在处理后36小时，而分析染色体畸变时为30小时。在微核试验中，最低有效剂量为25毫克/千克，而以畸变作为诱变终点时，在6.25毫克/千克时观察到显著效应（P小于0.001）。结果表明，在两种试验中采用单次处理和不同取样间隔，在最大反应时，畸变分析比微核试验具有更高的分辨能力。鉴于欧洲经济共同体和经济合作与发展组织目前正在制定的指导方针，讨论了两种骨髓试验常规应用的合适方案。提出了反对亚急性处理方案和支持单次处理及多个取样间隔方案的论据。
